What is the recommended management for an 8 mm non‑solid pulmonary nodule with no solid component that is unchanged on the first follow‑up low‑dose CT performed at one year?

Management of 8 mm Non-Solid Pulmonary Nodule Unchanged at 1-Year Follow-Up

Continue annual CT surveillance for at least 5 years total, with the next scan scheduled in approximately 1 year (at the 2-year mark from initial detection).

Rationale and Evidence-Based Approach

For your 8 mm pure ground-glass nodule (non-solid, no solid component) that has remained stable at the 1-year follow-up, the most recent and highest-quality guidelines provide clear direction:

Primary Recommendation

The 2017 Fleischner Society guidelines 1 specifically address this scenario for non-solid nodules ≥6 mm:

• Initial CT at 6-12 months to confirm persistence (which you've completed)
• Continue CT surveillance every 2 years until 5 years total

The 2024 AATS expert consensus 2 reinforces this approach, recommending:

• After confirming persistence at 6 months, follow-up CT at 12-24 month intervals
• Continue surveillance for at least 5 years for persistent pure ground-glass nodules

Why This Extended Surveillance?

Pure ground-glass nodules have unique biological behavior that justifies prolonged monitoring:

• Slow growth pattern: The average growth period for non-solid nodules is 3-4 years 2
• Malignancy risk: While 10-50% of persistent ground-glass nodules >10 mm may be malignant 3, they typically represent indolent adenocarcinomas (adenocarcinoma in situ or minimally invasive adenocarcinoma)
• Late growth detection: Studies show that growing nodules may not demonstrate changes until 3-4 years after initial detection 2

Technical Specifications for Follow-Up

Your surveillance imaging should include:

• Low-dose, non-contrast CT 4
• Thin-section reconstructions (≤1.5 mm, typically 1.0 mm) through the nodule 4, 1
• Volumetric measurements when possible for more accurate growth assessment 1

Critical Monitoring Points

Watch for these changes that would trigger more aggressive evaluation:

1. Development of a solid component - This significantly increases malignancy risk and warrants consideration of resection 4, 2
2. Growth in size - Any increase in diameter or volume
3. Increased density/attenuation - Suggests progression to invasive disease
4. Morphologic changes - Development of irregular margins, spiculation, or architectural distortion

Important Caveats

Patient-specific considerations may modify this approach:

• Life-limiting comorbidities: Patients with significant comorbidities where a low-grade malignancy would not impact survival may opt for limited or no further follow-up 4
• Patient preference: Some patients who place high value on avoiding treatment of potentially indolent cancers may choose less intensive surveillance 4
• Size >10 mm: If your nodule were >10 mm, earlier follow-up at 3 months might be indicated 4

Comparison with Older Guidelines

The 2013 ACCP guidelines 4 recommended annual surveillance for at least 3 years for non-solid nodules >5 mm. The more recent 2017 Fleischner 1 and 2024 AATS 2 guidelines have extended this to 5 years, reflecting better understanding of the natural history of these lesions.

Practical Algorithm

Your specific pathway:

1. ✓ Baseline CT (completed)
2. ✓ 1-year follow-up CT showing stability (completed)
3. → Next CT at 2 years from baseline (approximately 1 year from now)
4. → CT at 4 years from baseline (if stable)
5. → Final CT at 5 years from baseline (if stable)
6. → Discharge from surveillance if stable throughout

If any concerning changes develop: Proceed to multidisciplinary evaluation for possible PET/CT, biopsy, or surgical resection depending on the specific changes observed.